- Report
- February 2022
- 360 Pages
United States
From €3475EUR$3,600USD£2,981GBP
- Report
- November 2021
- 222 Pages
Global
From €2896EUR$3,000USD£2,484GBP
- Report
- March 2021
- 240 Pages
United States
From €2896EUR$3,000USD£2,484GBP
- Report
- June 2020
- 753 Pages
Global
From €3185EUR$3,300USD£2,732GBP
- Report
- February 2020
- 600 Pages
Global
From €3861EUR$4,000USD£3,312GBP
- Report
- August 2022
- 148 Pages
Global
From €5309EUR$5,500USD£4,554GBP
- Report
- March 2021
- 143 Pages
Global
From €1327EUR$1,375USD£1,138GBP
€2654EUR$2,750USD£2,277GBP
- Report
- October 2018
- 141 Pages
Global
From €603EUR$625USD£517GBP
€1206EUR$1,250USD£1,035GBP
- Report
- January 2023
- 189 Pages
Global
From €4054EUR$4,200USD£3,477GBP
- Report
- December 2020
- 164 Pages
Global
From €4778EUR$4,950USD£4,098GBP
- Report
- April 2019
- 115 Pages
Global
From €1342EUR$1,390USD£1,151GBP
- Report
- April 2023
- 119 Pages
Global
From €4585EUR$4,750USD£3,933GBP
- Report
- April 2023
- 110 Pages
Global
From €4585EUR$4,750USD£3,933GBP
- Report
- April 2023
- 350 Pages
Global
From €3137EUR$3,250USD£2,691GBP
- Drug Pipelines
- December 2022
- 30 Pages
Global
From €3137EUR$3,250USD£2,691GBP
- Drug Pipelines
- December 2022
- 30 Pages
Global
From €3137EUR$3,250USD£2,691GBP
- Report
- October 2022
- 300 Pages
Global
From €3813EUR$3,950USD£3,270GBP
- Report
- September 2022
- 239 Pages
Global
From €7239EUR$7,500USD£6,210GBP
- Drug Pipelines
- January 2022
- 200 Pages
Global
From €7239EUR$7,500USD£6,210GBP
- Report
- January 2022
- 224 Pages
Global
From €6708EUR$6,950USD£5,754GBP
Pembrolizumab is a type of oncology drug used to treat certain types of cancer. It is a monoclonal antibody, which works by targeting and blocking a protein called PD-1, which is found on the surface of some cancer cells. This helps the body's immune system to recognize and attack the cancer cells. Pembrolizumab is used to treat a variety of cancers, including melanoma, non-small cell lung cancer, head and neck cancer, Hodgkin lymphoma, and urothelial carcinoma. It is also used in combination with other drugs to treat certain types of advanced or metastatic cancers.
Pembrolizumab is approved by the US Food and Drug Administration (FDA) and is available in the US and other countries. It is typically administered intravenously, and the dosage and duration of treatment depend on the type and stage of cancer being treated.
Some companies in the Pembrolizumab market include Merck & Co., Inc., Bristol-Myers Squibb, AstraZeneca, and Roche. Show Less Read more